Webinar for Collaboration Opportunities with 6 Leading Japanese Pharmaceutical Companies

Image for Webinar for Collaboration Opportunities with 6 Leading Japanese Pharmaceutical Companies

The Department for Business and Trade (DBT) Japan will be hosting the 4th Reverse Pitch Webinar inviting speakers from pre-clinical stage R&D / Business Development from the leading 6 Japanese pharmaceutical companies: Astellas Pharma Inc, Daiichi Sankyo Co Ltd, Eisai Co Ltd, Mitsubishi Tanabe Pharma Corporation, Shionogi & Co Ltd and Takeda Pharmaceutical Company Limited.

This webinar, open to UK headquartered companies and universities, will provide the ideal opportunity to learn the latest research priorities and collaboration structures of the leading Japanese pharmaceutical companies.

Date:                     10th July, 2024

Time:                    09:00 – 10:35 UK Time

Location:             Online (Zoom)

Deadline:            Please register by 9th July – contact SPO Nicola White


09:00               Opening Remarks / Housekeeping

09:05-09:20     Astellas Pharma Inc

09:20-09:35     Daiichi Sankyo Co Ltd

09:35-09:50     Eisai Co Ltd

09:50-10:05     Mitsubishi Tanabe Pharma Corporation

10:05-10:20     Shionogi & Co Ltd

10:20-10:35     Takeda Pharmaceutical Company Limited

10:35               Closing

*Q&A Moderator: Dr Ivana Poparic, Head of Life Sciences Cluster Development, MedCity / London & Partners

Astellas Pharma Inc

Astellas is interested in emerging areas of drug discovery & development including new biological insights, platforms, and modalities across multiple therapeutic areas.

Daiichi Sankyo Co Ltd

Daiichi Sankyo is seeking early-stage technology platform-based opportunities for research collaboration with academia or startups.



Eisai Co Ltd



Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma is exploring for research collaboration and partnership opportunities for drug discovery technologies below, in addition to drug candidates and drug targets in our focused therapeutic areas of neurological/autoimmune diseases and refractory cancers.

Drug Discovery Technologies

Shionogi & Co Ltd

(NTM*: Nontuberculous Mycobacteria)

Shionogi Wish List

Takeda Pharmaceutical Company Ltd

Takeda is seeking partners with innovative therapeutic candidates and technologies in the fields of Neuroscience, Oncology, and Gastrointestinal & Inflammation.

Posted on 20/06/2024